It could very well be possible. With 17% short interest and with approval of Byetta and Symlin they are going to be generating revenue fairly soon. This is an interesting wrinkle from the article also:
One side effect of Byetta--in addition to nausea--is weight loss, which Kliff views as a positive for diabetics. Patients taking Lantus, says Kliff, tend to gain weight. Early clinical data for another Amylin candidate, Pramlintide, also shows potential for use as a weight-loss agent.
There have been insane problems with weight-loss drugs in the past. (ie Fen Phen) But if Pramlintide does allow people to lose wieght with minor side effects it will be a massive blockbuster. The promise of weight loss with no exercise and no change in eating habits would be like finding the Holy Grail in the rapidly fattening US.
No comments:
Post a Comment